Celebrating a Year of Innovation

​​​

As we wrap up 2024, we reflect on a year filled with strengthened commitment to patients, dedication to research and developing life-saving therapies. It has been a remarkable year, with new achievements, more recognitions, partnerships, and a growing network of collaborators.

​

Reflecting on a Year of Achievements

​

As we approach this holiday season, I reflect on our team’s achievements. First, I would like to express my gratitude to so many amazing people’s unwavering support throughout this year.  This past year not only we expanded our team, we also have had many new advisors and advocates joining us who are guiding us and believe in our shared mission and vision. 

​

In 2024, we welcomed new team members including Dr. Zsuzsanna Devecseri, an accomplished physician and Pharma executive at Novartis to our Board of Directors, Dr. Christy Hunter, a gifted chemist to lead our many chemistry, peptide and nucleic acid design projects, as the Director of Chemistry and Mr. Theo Godfrey, an advocate for rare pediatric diseases and a distinguished corporate venture capital lawyer and a legal partner at CMS Cameron McKenna Nabarro Olswang LLP, to our Business and Patient Advocacy Advisory Board.  In 2025, we look forward to welcoming additional team members for our growing R & D.

​

This past year, our team has had the honor of receiving more recognitions and awards. 

I am extremely proud that for the fifth consecutive year, Professor Moein Moghimi, pioneering scientist and inventor of our Peptide Therapeutic Platforms and our esteemed Dr. Christy Hunter have been named to the List of World’s Most Cited researchers. Every year, Stanford University and Elsevier’s publish their “Updated Science-Wide Author Databases of Standardized Citation Indicators”. This prestigious database highlights top scientists globally, showcasing their impact across 22 scientific disciplines and 174 sub-fields and provides career long data (to the end-of-2023 and single year (2023) data). This prestigious list has named Professor Moghimi among the world’s leading top 0.036% of scientists (only 8000 scientists in the world) on a career long basis.  He has been recognized as #4 (#9 including those retired and inactive) scientist and researcher in the UK in Pharmacology and Pharmacy, and #46 (including those retired and inactive) in the world among 148,458 scientists in Pharmacology and Pharmacy.  Dr. Hunter has been recognized among the top 2% of the scientists in all fields, across 22 scientific disciplines and 174 sub-fields. I extend my warmest congratulations to both scientists.

​

Earlier this year we received several recognitions. SMDG was a finalist in two categories at the Pharma Industry Award UK 2024. SMDG was recognized as a finalist in the category; Research and Development Achievement Award: Pioneering Therapeutic Platforms and Women in Pharma.

​

Just about a couple of weeks ago, I found out that I have been recognized for the Northern Power House Ethnic Minority Thought Leaders Powerlist. This recognition follows two other recognitions earlier in the year.  This past summer, I was recognized as one of the finalists for the UK Women in Pharma Award and in March, I was also honored to be the recipient of the SME News- CEO of the Year Awards for CEO leading Most Innovative Company with life-saving therapies.  I feel a great sense of joy and honor to receive such prestigious recognitions in 2024.  Over the years, not only, I have strived to work towards bringing life-saving therapies to patients suffering from debilitating diseases including neurodegenerative and rare pediatric diseases. I have also continued my efforts on promoting health equity and improving educational opportunities globally. 

​

This past year, we have also had the privilege of participating in key industry events worldwide in 2024, virtually and in person, where we showcased and introduced our research and award-winning Peptide Therapeutic Platforms and discussed the most relevant research updates. Please get in touch if you would like to meet us at one of the many conferences we will be attending.  We have already accepted attending and giving talks at three conferences and we know there will be many more to attend. 

​

Another major step in our growth this year, has been the design and launch of our Artificial Intelligence and Machine Learning (AI/ML) platform.  This has been a significant step for our company in expanding our therapeutic discovery and development processes and identification of new biomarkers which will help us to design additional novel therapies.  Our platform was also this past summer shortlisted and advanced to the second stage for the Roddenberry Foundation Prize.  We look forward to sharing more with you in the coming months. 

​

Finally, developing medicines require collaboration and diligence in bringing the best and safest therapies to patients. We believe in the power of partnerships and research collaborations. We know that it is always difficult to introduce something so pioneering and industry-changing like our platforms that could transform tomorrow's medicines.  This past year, we established a number of new research collaborations across the world and we will be updating you on them throughout the year. We also eagerly seek and look forward to many more collaborations and partnerships in the New Year.

​

Looking Ahead to 2025

​

As we prepare to embark on a new year, our focus remains on innovation, collaboration, and most importantly, the well-being of patients. Our commitment to patients remains at the heart of everything we do.

​

I look forward to a dynamic year ahead. Let's embark on this new journey together, filled with possibilities, achievements, and a shared vision for a brighter tomorrow. Together, we will shape the future of healthcare and make a difference in the lives of patients worldwide and don't forget to stay tuned for exciting developments and announcements in the coming year. 

​

Shadi 

​

December 2024

​

​

​